Strong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical Developments
Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report), retaining the ...
Promising Clinical Outcomes and Financial Stability Support Buy Rating for Black Diamond Therapeutics
TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating today. Marc Frahm’s rating is based ...